After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Jupiter Neurosciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Jupiter Neurosciences Inc is $93.02M. A total of 0.88 million shares were traded on the day, compared to an average of 464.08K shares.
In the most recent transaction, Silva Alison D. bought 750 shares of JUNS for 1.03 per share on Jul 01 ’25. After the transaction, the Pres + Chief Business Officer now owns 112,777 company shares. In a previous transaction on Jul 01 ’25, ROSEN CHRISTER bought 3,600 shares at 1.02 per share. JUNS shares that CEO and Chairman owns now total 11,078,892.
Among the insiders who bought shares, Silva Alison D. acquired of 950 shares on Jun 30 ’25 at a per-share price of $1.03. This resulted in the Pres + Chief Business Officer holding 112,027 shares of JUNS after the transaction. In another insider transaction, Silva Alison D. bought 850 shares at $1.03 per share on Jun 27 ’25. Company shares held by the Pres + Chief Business Officer now total 111,077.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, JUNS has a high of $19.51 and a low of $0.51.
As of this writing, JUNS has an earnings estimate of -$0.07 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.07 per share and a lower estimate of -$0.07.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. JUNS’s latest balance sheet shows that the firm has $330.60k in Cash & Short Term Investments as of fiscal 2021. There were $651.20k in debt and $5.68M in liabilities at the time. Its Book Value Per Share was $0.09, while its Total Shareholder’s Equity was -$5.18M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JUNS is Buy with a score of 5.00.
